{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T07:28:10Z","timestamp":1784186890056,"version":"3.55.0"},"update-to":[{"DOI":"10.1002\/14651858.cd010961","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:00:00Z","timestamp":1681430400000}}],"reference-count":52,"publisher":"Wiley","issue":"4","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010961.pub2","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T11:19:04Z","timestamp":1681471144000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Perampanel add-on for drug-resistant focal epilepsy"],"prefix":"10.1002","volume":"2023","author":[{"given":"Rebecca","family":"Bresnahan","sequence":"additional","affiliation":[{"name":"Liverpool Reviews and Implementation Group, Department of Health Data Science; University of Liverpool; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruaraidh A","family":"Hill","sequence":"additional","affiliation":[{"name":"Liverpool Reviews and Implementation Group, Department of Health Data Science; University of Liverpool; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology; The First Affiliated Hospital, Guangxi Medical University; Nanning China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,4,14]]},"reference":[{"issue":"6","key":"10.1002\/14651858.CD010961.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1212\/WNL.0b013e3182635735","article-title":"Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304","volume":"79","author":"French","year":"2012","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD010961.pub2-BIB0002|cit2","unstructured":"Evaluating the efficacy and safety of E2007 (perampanel) given as adjunctive therapy in subjects with refractory partial seizures www.clinicaltrials.gov\/ct2\/show\/NCT00699972"},{"issue":"1","key":"10.1002\/14651858.CD010961.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1528-1167.2012.03638.x","article-title":"Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305","volume":"54","author":"French","year":"2013","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD010961.pub2-BIB0004|cit4","unstructured":"To evaluate the efficacy and safety of E2007 (perampanel) given as adjunctive therapy in subjects with refractory partial seizures www.clinicaltrials.gov\/ct2\/show\/NCT00699582"},{"issue":"18","key":"10.1002\/14651858.CD010961.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1212\/WNL.0b013e318254473a","article-title":"Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures","volume":"78","author":"Krauss","year":"2012","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD010961.pub2-BIB0006|cit6","unstructured":"Evaluating efficacy and safety of E2007 (perampanel) given as adjunctive therapy in subjects with refractory partial seizures www.clinicaltrials.gov\/ct2\/show\/NCT00700310"},{"key":"10.1002\/14651858.CD010961.pub2-BIB0007|cit7","unstructured":"Research study to investigate an additional treatment for patients with epilepsy www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-004293-24\/GB"},{"issue":"1","key":"10.1002\/14651858.CD010961.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1600-0404.2011.01588.x","article-title":"Tolerability and safety of perampanel: two randomized dose-escalation studies","volume":"125","author":"Krauss","year":"2012","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1002\/14651858.CD010961.pub2-BIB0009|cit9","unstructured":"E2007 given as adjunctive therapy in patients with refractory partial seizures www.clinicaltrials.gov\/ct2\/show\/NCT00144690"},{"key":"10.1002\/14651858.CD010961.pub2-BIB0010|cit10","unstructured":"Exploring the safety and tolerability of doses of E2007 up to a maximum of 12 mg In patients with refractory partial seizures www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2006-003702-26"},{"issue":"1","key":"10.1002\/14651858.CD010961.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1600-0404.2011.01588.x","article-title":"Tolerability and safety of perampanel: two randomized dose-escalation studies","volume":"125","author":"Krauss","year":"2012","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1002\/14651858.CD010961.pub2-BIB0012|cit12","unstructured":"Exploring the safety and tolerability of doses of E2007 up to a maximum of 12 mg in patients with refractory partial seizures www.clinicaltrials.gov\/ct2\/show\/NCT00416195"},{"key":"10.1002\/14651858.CD010961.pub2-BIB0013|cit13","unstructured":"A study with an open-label extension phase to evaluate the effect of perampanel (E2007) on cognition, growth, safety, tolerability, and pharmacokinetics in adolescents www.clinicaltrialsregister.eu\/ctr-search\/search?query=EUCTR2010-018518-56-LV"},{"issue":"7","key":"10.1002\/14651858.CD010961.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/epi.13417","article-title":"Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: a randomized study evaluating behavior, efficacy, and safety","volume":"57","author":"Lagae","year":"2016","journal-title":"Epilepsia"},{"issue":"2","key":"10.1002\/14651858.CD010961.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/epi.13279","article-title":"Cognitive effects of adjunctive perampanel for partial-onset seizures: a randomized trial","volume":"57","author":"Meador","year":"2016","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD010961.pub2-BIB0016|cit16","unstructured":"A study with an open-label extension phase to evaluate the effect of perampanel (E2007) on cognition, growth, safety, tolerability, and pharmacokinetics in adolescents www.clinicaltrials.gov\/ct2\/show\/NCT01161524"},{"key":"10.1002\/14651858.CD010961.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.eplepsyres.2016.08.025","article-title":"Pharmacokinetics, exposure-cognition, and exposure-efficacy relationships of perampanel in adolescents with inadequately controlled partial-onset seizures","volume":"127","author":"Villanueva","year":"2016","journal-title":"Epilepsy Research"},{"key":"10.1002\/14651858.CD010961.pub2-BIB0018|cit18","unstructured":"A study with an open-label extension phase to evaluate the efficacy and safety of perampanel (E2007) administered as an adjunctive therapy in subjects with refractory partial-onset seizures www.clinicaltrials.gov\/ct2\/show\/NCT01618695"},{"issue":"4","key":"10.1002\/14651858.CD010961.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1111\/ane.12883","article-title":"Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study","volume":"137","author":"Nishida","year":"2018","journal-title":"Acta Neurologica Scandinavica"},{"issue":"11","key":"10.1002\/14651858.CD010961.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1212\/WNL.0000000000001930","article-title":"Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy: a randomized trial","volume":"85","author":"French","year":"2015","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD010961.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1528-1167.2012.03648.x","article-title":"Perampanel, a selective, noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307","volume":"54","author":"Krauss","year":"2013","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD010961.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.eplepsyres.2015.04.011","article-title":"Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel","volume":"114","author":"Montouris","year":"2015","journal-title":"Epilepsy Research"},{"key":"10.1002\/14651858.CD010961.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.yebeh.2016.08.004","article-title":"Sleep quality and daytime sleepiness in patients treated with adjunctive perampanel for focal seizures","volume":"63","author":"Toledo","year":"2016","journal-title":"Epilepsy & Behavior"},{"key":"10.1002\/14651858.CD010961.pub2-BIB0024|cit24","unstructured":"Safety and pharmacokinetics study of E2007 to treat partial and generalised seizures in people with epilepsy clinicaltrials.gov\/ct2\/show\/nct03780907"},{"issue":"4","key":"10.1002\/14651858.CD010961.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"4","key":"10.1002\/14651858.CD010961.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.neuint.2012.02.035","article-title":"A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus","volume":"61","author":"Ceolin","year":"2012","journal-title":"Neurochemistry International"},{"key":"10.1002\/14651858.CD010961.pub2-BIB0027|cit27","unstructured":"European Medicines Agency Fycompa (perampanel) www.ema.europa.eu\/en\/documents\/overview\/fycompa-epar-medicine-overview_en.pdf"},{"key":"10.1002\/14651858.CD010961.pub2-BIB0028|cit28","unstructured":"Clinical safety review: fycompa (perampanel) www.fda.gov\/media\/92787\/download"},{"issue":"3","key":"10.1002\/14651858.CD010961.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1212\/WNL.0000000000003509","article-title":"Prevalence and incidence of epilepsy","volume":"88","author":"Fiest","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD010961.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.phrs.2012.12.006","article-title":"Novel treatment options for epilepsy: focus on perampanel","volume":"70","author":"Franco","year":"2013","journal-title":"Pharmacological Research"},{"key":"10.1002\/14651858.CD010961.pub2-BIB0031|cit31","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime, Inc)"},{"issue":"7","key":"10.1002\/14651858.CD010961.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/j.1528-1167.2011.03109.x","article-title":"Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy","volume":"52","author":"Hanada","year":"2011","journal-title":"Epilepsia"},{"issue":"1","key":"10.1002\/14651858.CD010961.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1212\/01.wnl.0000438226.10353.1c","article-title":"The questionable use of unequal allocation in confirmatory trials","volume":"82","author":"Hey","year":"2014","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD010961.pub2-BIB0034|cit34","unstructured":"Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1\/"},{"issue":"10","key":"10.1002\/14651858.CD010961.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s40263-013-0091-9","article-title":"Systematic review and meta-analysis of the efficacy and safety of perampanel in the treatment of partial-onset epilepsy","volume":"27","author":"Hsu","year":"2013","journal-title":"CNS Drugs"},{"issue":"8","key":"10.1002\/14651858.CD010961.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1185\/03007995.2013.803461","article-title":"The efficacy and tolerability of perampanel and other recently approved anti-epileptic drugs for the treatment of refractory partial onset seizure: a systematic review and Bayesian network meta-analysis","volume":"29","author":"Khan","year":"2013","journal-title":"Current Medical Research and Opinion"},{"issue":"3","key":"10.1002\/14651858.CD010961.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/epi.12527","article-title":"Perampanel for adjunctive treatment of partial-onset seizures: a pooled dose-response analysis of phase III studies","volume":"55","author":"Kramer","year":"2014","journal-title":"Epilepsia"},{"issue":"6","key":"10.1002\/14651858.CD010961.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD010961.pub2-BIB0039|cit39","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Marshall C Technical Supplement to Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston MS, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook"},{"issue":"10","key":"10.1002\/14651858.CD010961.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1212\/WNL.0b013e31822cfc90","article-title":"Incidence of epilepsy: a systematic review and meta-analysis","volume":"77","author":"Ngugi","year":"2011","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD010961.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1358\/dot.2013.49.1.1906424","article-title":"Perampanel: a novel antiepileptic for the adjunctive treatment of refractory partial onset seizures","volume":"49","author":"Owen","year":"2013","journal-title":"Drugs of Today (Barcelona, Spain: 1998)"},{"issue":"12","key":"10.1002\/14651858.CD010961.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s40263-012-0021-2","article-title":"Perampanel: as adjunctive therapy in patients with partial-onset seizures","volume":"26","author":"Plosker","year":"2012","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1002\/14651858.CD010961.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1517\/14656566.2013.754883","article-title":"Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures","volume":"14","author":"Rektor","year":"2013","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1002\/14651858.CD010961.pub2-BIB0044|cit44","unstructured":"Review Manager 5 (RevMan 5) Nordic Cochrane Centre, The Cochrane Collaboration 2014"},{"issue":"2","key":"10.1002\/14651858.CD010961.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"56","DOI":"10.5698\/1535-7511-11.2.56","article-title":"Revisiting AMPA receptors as an antiepileptic drug target","volume":"11","author":"Rogawski","year":"2011","journal-title":"Epilepsy Currents"},{"key":"10.1002\/14651858.CD010961.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/ane.12100","article-title":"Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist","volume":"197","author":"Rogawski","year":"2013","journal-title":"Acta Neurologica Scandinavica Supplementum"},{"issue":"1-2","key":"10.1002\/14651858.CD010961.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0920-1211(02)00065-7","article-title":"The clinical impact of new antiepileptic drugs after a decade of use in epilepsy","volume":"50","author":"Schmidt","year":"2002","journal-title":"Epilepsy Research"},{"issue":"6","key":"10.1002\/14651858.CD010961.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S1474-4422(08)70108-X","article-title":"Intractable epilepsy: management and therapeutic alternatives","volume":"7","author":"Schuele","year":"2008","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD010961.pub2-BIB0049|cit49","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available from gdt.guidelinedevelopment.org\/app\/handbook\/handbook.html"},{"issue":"2","key":"10.1002\/14651858.CD010961.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1586\/ern.12.154","article-title":"Perampanel: newly approved, novel antiepileptic medication for partial-onset seizures","volume":"13","author":"Shvarts","year":"2013","journal-title":"Expert Review of Neurotherapeutics"},{"issue":"8","key":"10.1002\/14651858.CD010961.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/epi.12212","article-title":"Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies","volume":"54","author":"Steinhoff","year":"2013","journal-title":"Epilepsia"},{"issue":"2","key":"10.1002\/14651858.CD010961.pub2-BIB0052|cit52","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010961","article-title":"Perampanel add-on for drug-resistant partial epilepsy","author":"Huang","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:04:54Z","timestamp":1733702694000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010961.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Epilepsy Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,4,14]]},"references-count":52,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010961.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,14]]}}}